



[Science](#)[Education](#)[Patient Care](#)

[Our Society](#)[Our Mission, Vision & Values](#)[EBMT Membership 2025](#)[Organisational Structure 2025](#)[Financial Highlights 2025](#)[EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Annalisa Ruggeri
CTIWP Chair
Italy

Major achievements

The CTIWP continues to expand in parallel with the growing application of cell therapies across a wide range of diseases. Important achievement has been reached with more than 16,000 cases of CAR T reported to the EBMT Registry and continuing the collaboration with other Working Parties and partner societies, including GoCART and the EHA. The EBMT-EHA European CAR T-cell Meeting represents an

important focus on the new translational and clinical findings on cell therapies with distinguished speakers worldwide.

The research activity of the CTIWP is broad and focuses on multiple factors influencing outcomes after transplants and CAR T-cell therapy. Two important studies on the outcomes of CAR T in older patients have been completed highlighting the feasibility of this innovative treatment regardless the limits of age. Furthermore a cross sectional survey on the fertility after CART demonstrated how fertility preservation is possible with more than 15 successful pregnancies reported in young patients treated with CART.

Principal research studies

[Use of regulatory T cells for GvHD prophylaxis and therapy in Europe](#)

[Study type](#)

[Closed Survey/Study](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Federico Simonetta](#)

[Real-World Use of Post-Transplant Cyclophosphamide \(PTCy\) for Graft-Vs-Host-Disease \(GVHD\) Prophylaxis in Transplant Centers](#)

[Study type](#)

[Closed Survey/Study](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Elias Shlomo](#)

[Outcomes of patients over 70 years treated with brexucabtagene autoleucel for relapsed refractory mantle cell lymphoma: a study from the CTIWP of EBMT](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Other myeloid or lymphoid malignancies](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Type of treatment](#)

[CAR T](#)

[Principal investigator](#)

[Nicole Santoro](#)

[Nutritional Care Practices during CAR-T Cell Treatment in Adult Patients](#)

[Study type](#)

[Closed Survey/Study](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Nursing Research Committee](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Type of treatment](#)

[CAR T](#)

[Principal investigator](#)

[Paolo Pedrazzoli](#)

[Survey on fertility procedures and outcomes for patients treated with CAR-T cell](#)

[therapy](#)

[Study type](#)

[Closed Survey/Study](#)

[Diseases](#)

[All diseases](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Type of treatment](#)

[CAR T](#)

[Principal investigator](#)

[Giorgio Orofino](#)

Key publications

[2025](#)

[The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[1st listed author](#)

[L G M Daenen](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2025](#)

[The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[1st listed author](#)

[Simona Pagliuca](#)

[Journal](#)

[Blood Rev.](#)

[2025](#)

[Current use of donor lymphocyte infusions after allogeneic stem cell transplantation in Europe: a survey on behalf of the cellular therapy and immunobiology working party of the EBMT](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[1st listed author](#)

[Nicole Santoro](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2025](#)

[CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT cellular therapy and immunobiology working party](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[1st listed author](#)

[Nina Worel](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2025](#)

[Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee](#)

[Group](#)

[Complications Working Party \(CWP\)](#)

[Practice Harmonisation and Guidelines Committee](#)

[1st listed author](#)

[Charlotte E Graham](#)

[Journal](#)

[Lancet Oncol.](#)


[See the full list of the CTIWP 2025 publications](#)



Indicators

	2023	2024	2025
Impact factor	103.14	119.00	129.20
Oral presentations	7	7	9
Poster presentations	4	7	9
Educational events	5	2	3

Major educational events



[Event](#)

[FHA-FBMT 7th European CAR T-cell Meeting](#)



[ce](#)

[Event](#)

51st Annual Meeting of the EBMT



Event

Acute Leukaemia and Cellular Therapy and Immunobiology Working Parties Joint Transplant Programme Track at the 8th Annual Meeting of the IACH

Oct 09, 2025 - Oct 11, 2025 / Paris, France

Discover more

VISIT THE CTIWP WEBPAGE